Drug Trial Radar · NCT04606433
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
47
Actual
Start
Nov 4, 2020
Primary completion
Dec 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- SystImmune Inc.
- First posted
- Oct 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open, multicenter, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics/pharmacokinetics, and antitumor activity of GNC-038 quad-specific antibody injection in relapsed or refractory non-Hodgkin's lymphoma, relapsed or refractory acute lymphoblastic leukemia, and refractory or metastatic solid tumors.
Conditions
- Non Hodgkin Lymphoma
- Acute Lymphoblastic Leukemia
Interventions
GNC-038Drug
Administration by intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT)Time frame: Up to 14 days after the first dose
- Maximum tolerated dose (MTD) or maximum administrated dose (MAD)Time frame: Up to 14 days after the first dose
- Treatment-Emergent Adverse Event (TEAE)Time frame: Up to approximately 24 months
- The recommended dose for future clinical studyTime frame: Up to 14 days after the first dose of GNC-038
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Xiangya Hospital Central South University
Changsha, Hunan, China
Shanghai Tongji Hospital
Shanghai, Shanghai Municipality, China
Hematology Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.